Trial Profile

LVAD Therapy: Exploring the Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Oct 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rexlemestrocel-L (Primary)
Indications Heart failure
Focus Adverse reactions

Most Recent Events

09 Oct 2018 According to a Mesoblast media release, National Institutes of Health has funded this study.
21 Dec 2017 According to a Mesoblast media release, based on the data of this trial, the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for mesenchymal precursor cell (MPC) therapy to treat patients with heart failure with LVSD and LVADs.
20 May 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com